Coherus Oncology
CHRS
86 hedge funds and large institutions have $428M invested in Coherus Oncology in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 43 increasing their positions, 10 reducing their positions, and 11 closing their positions.
330% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 10
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
15% more funds holding
Funds holding: 75 → 86 (+11)
11% more capital invested
Capital invested by funds: $385M → $428M (+$43.2M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
95% less call options, than puts
Call options by funds: $21K | Put options by funds: $432K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
+$57.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$33M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$12.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.96M |
| 5 |
Millennium Management
New York
|
+$7.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$27M |
| 2 |
BM
Bridger Management
New York
|
-$7.24M |
| 3 |
JP Morgan Chase
New York
|
-$4.61M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.76M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.06M |
CHRS Hedge Fund Activity: Q2 2016 in Review
86 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2016, worth a combined $428M — up 11% from $385M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CHRS positions and 11 closed out — a net gain of 12 holders — while 43 added to existing stakes and 10 trimmed.
The largest buyer was Kohlberg Kravis Roberts & Co, opening a new position worth an estimated $57.4M. The largest seller was RA Capital Management, exiting entirely with an estimated $27M sold.
- 86 institutional investors held Coherus Oncology (CHRS) as of Q2 2016, up from 75 in Q1 2016.
- Funds reported $428M of Coherus Oncology stock for Q2 2016, up 11% quarter-over-quarter.
- 23 funds opened new Coherus Oncology positions in Q2 2016 and 11 closed out, a net change of +12 holders.
- The largest Coherus Oncology buyer in Q2 2016 was Kohlberg Kravis Roberts & Co, an estimated $57.4M added.
- The largest Coherus Oncology seller in Q2 2016 was RA Capital Management, an estimated $27M sold.
Based on aggregated 13F filings for Q2 2016.